Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

5.710 -0.080 (-1.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Analyst Ratings for Replimune Group
 
Via Benzinga
Replimune Group: Q2 Earnings Insights
Replimune Group (NASDAQ:REPL) reported its Q2 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform
Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. 
Via Benzinga
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday
 
Via Benzinga
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
Analyst Ratings for Replimune Group
Analysts have provided the following ratings for Replimune Group (NASDAQ:REPL) within the last quarter: 
Via Benzinga
Replimune Group: Q3 Earnings Insights
  Replimune Group (NASDAQ:REPL) reported its Q3 earnings results on Thursday, February 3, 2022 at 08:00 AM. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts
 
Via Benzinga
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday
Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68... 
Via Benzinga
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
Replimune Group: Q4 Earnings Insights
Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Replimune Group missed... 
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Telsey Advisory Group boosted the price target for Burlington Stores, Inc. (NYSE: 
Via Benzinga
55 Biggest Movers From Yesterday
Gainers DLocal Limited (NASDAQ: DLO) shares jumped 54.2% to close at $32.39 on Thursday. DLocal raised around $92.6 million from the sale of 4.4 million shares in its IPO. GTT... 
Via Benzinga
Topics Initial Public Offering
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Kindred Biosciences (NASDAQ:KIN) shares increased by 24.08% to $6.75 during Thursday's regular session. Kindred Biosciences's stock is trading at a volume... 
Via Benzinga
46 Stocks Moving In Thursday's Mid-Day Session
Gainers GTT Communications, Inc. (NYSE: GTT) shares jumped 66% to $4.16 on abnormally-high volume. The company’s stock also jumped over 57% on Wednesday. Ra Medical Systems... 
Via Benzinga
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 2) BioCryst Pharmaceuticals,... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Chiasma (NASDAQ:CHMA) shares moved upwards by 41.9% to $4.03 during Wednesday's regular session. Chiasma's stock is trading at a volume of 75.5 million... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.